Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)

INTERVENTION: This will be an open, randomised comparison of two pentamidine treatment regimens, given over three days or seven days with a non‐inferiority trial design. CONDITION: Human African Trypanosomiasis (HAT) ; Infections and Infestations ; Human African Trypanosomiasis (HAT) PRIMARY OUTCOME: Proportion of cases with favourable progress at 6 months, based on clinical state and laboratory status. SECONDARY OUTCOME: 1. Proportion of cases with favourable progress at discharge, 3 and 12 months based on clinical state and laboratory status; 2. Cure rate at 18 months, based on based on clinical state and laboratory status; 3. Frequency and severity of adverse events INCLUSION CRITERIA: 1. Aged more than or equal to 14 years and less than 60 years 2. Parasite positive (on examination of lymph juice, by Capillary Tube Centrifugation [CTC] or miniature Anion‐Exchange Centrifugation [mAEC] on whole blood) 3. Alternative diagnoses excluded clinically and by appropriate laboratory investigations 4. Capable of and giving informed consent to the study